Michael Zand – Page 80

3 Things In Biotech, May 19: Buy BMY? Oncolytics In Again? Atara’s Immunotherapy Data – Seeking Alpha

2018-05-20 Michael Zand NEWS

CRISPR Editing Stops HIV Virus in Infected Cells – Technology Networks

Technology NetworksCRISPR Editing Stops HIV Virus in Infected CellsTechnology NetworksBased on genetic information from six major HIV-1 subtypes, the team designed six types of guide RNA (gRNA) that enable specific genome editing using the CRISPR/Cas9 … Continue reading

2018-05-20 Michael Zand NEWS

AUA 2018: Translational Research to Potentiate Immunotherapy in Urothelial Cancer – UroToday

AUA 2018: Translational Research to Potentiate Immunotherapy in Urothelial CancerUroTodayPan asked the hypothetical question, “What can we do to improve immunotherapy in urothelial cancers?” Pan told the audience we need to improve patient selection an… Continue reading

2018-05-20 Michael Zand NEWS

AUA 2018: Translational Research to Potentiate Immunotherapy in Urothelial Cancer – UroToday

2018-05-20 Michael Zand NEWS

AUA 2018: Refining Immunotherapy Combinations and Sequencing in Bladder Cancer – UroToday

AUA 2018: Refining Immunotherapy Combinations and Sequencing in Bladder CancerUroTodayHe noted that immunotherapy is an exciting and well-tolerated agent in the treatment of urothelial carcinoma, however, only 15-20% of patients derive significant bene… Continue reading

2018-05-20 Michael Zand NEWS

AUA 2018: Refining Immunotherapy Combinations and Sequencing in Bladder Cancer – UroToday

2018-05-20 Michael Zand NEWS

AUA 2018: Immunotherapy in Renal Cell Carcinoma: Current Standing and Future Directions – UroToday

AUA 2018: Immunotherapy in Renal Cell Carcinoma: Current Standing and Future DirectionsUroTodayDr. Campbell began by exploring the historical and present use of high dose Interleukin-2 (IL-2), as the initial form of immunotherapy used for renal cell ca… Continue reading

2018-05-20 Michael Zand NEWS

1
…
78
79
80
81
82
…
3,823

Seeking Alpha

3 Things In Biotech, May 19: Buy BMY? Oncolytics In Again? Atara’s Immunotherapy Data
Seeking Alpha
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we’re talking about! Here is some more information if you’re curious. Welcome to another edition of “3 Things In …

and more »

Login

Cart

All posts by: Michael Zand

Gene therapy that reverses blindness in dogs could also help treat humans – News-Medical.net

3 Things In Biotech, May 19: Buy BMY? Oncolytics In Again? Atara’s Immunotherapy Data – Seeking Alpha

CRISPR Editing Stops HIV Virus in Infected Cells – Technology Networks

AUA 2018: Translational Research to Potentiate Immunotherapy in Urothelial Cancer – UroToday

AUA 2018: Translational Research to Potentiate Immunotherapy in Urothelial Cancer – UroToday

AUA 2018: Refining Immunotherapy Combinations and Sequencing in Bladder Cancer – UroToday

AUA 2018: Refining Immunotherapy Combinations and Sequencing in Bladder Cancer – UroToday

AUA 2018: Immunotherapy in Renal Cell Carcinoma: Current Standing and Future Directions – UroToday